Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kiromic BioPharma, Inc. - Common Stock (OP: KRBP )

1.200 UNCHANGED
Streaming Delayed Price Updated: 2:24 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 1.200
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 1.200
Today's Range 1.200 - 1.200
52wk Range 0.7769 - 3.650
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Kiromic BioPharma Reports Patient 4 in Deltacel-01 Clinical Trial Reaches 10-Month Progression-Free Survival
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Reports Tumor Volume Decrease in Two Patients Enrolled in Deltacel-01
From Kiromic BioPharma, Inc.
Via Business Wire

Performance

YTD
+33.33%
+33.33%
1 Month
+1.69%
+1.69%
3 Month
+26.32%
+26.32%
6 Month
-40.45%
-40.45%
1 Year
-22.58%
-22.58%

More News

Read More
Kiromic BioPharma Reports 32% Decrease in Tumor Volume Eight Months Post-Treatment in Fourth Patient Enrolled in Deltacel-01
From Kiromic BioPharma, Inc.
Via Business Wire
KRBP Stock Earnings: Kiromic BioPharma Reported Results for Q2 2024
Via InvestorPlace
Financial Crime Weekly: CEO Sentenced To 51 Months In Prison, Kiromic BioPharma Charged With Failure To Disclose Material Information
Via Benzinga
Topics Fraud
Exposures Legal
Kiromic BioPharma Announces Settlement of Previously Disclosed SEC Investigation
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Reports Favorable Ongoing Clinical Results From Fourth and Sixth Patients Enrolled in Deltacel-01
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Reports Favorable 10-Month Follow-Up Results for the First Patient Treated in its Deltacel-01 Clinical Trial
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Activates the University of Arizona Cancer Center as the Fifth Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee’s Unanimous Recommendation
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma’s Deltacel Receives FDA Fast Track Designation
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Provides Update on Part 1 of the Deltacel-01 Trial
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Reports 20% Tumor Size Reduction at Eight Months in First Patient Enrolled in Deltacel-01
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma to Advance Deltacel-01 Clinical Trial to Part 2, Expansion Phase
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Provides Updates on its Deltacel-01 Clinical Trial
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Reports Six-Month Results from First Patient Enrolled in Deltacel-01 Clinical Trial
From Kiromic BioPharma, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.